Adebrelimab
As of the edition of 20 October 2026, Adebrelimab is an antibody: in active development; acts on CD274.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2031
- Kind
- Antibody
- Registered trials
- 248, 0 stopped early
- Disease areas
- Cancer; Digestive system; Lungs and airways; Skin and connective tissue; Hormones; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD274 | Programmed cell death 1 ligand 1 | Q9NZQ7 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 11 | 0 | 9 | 0 |
| Phase 1 | 17 | 3 | 10 | 0 |
| Phase 2 | 203 | 1 | 174 | 0 |
| Phase 3 | 16 | 0 | 14 | 0 |
| Phase 4 | 1 | 0 | 0 | 0 |
| All trials | 248 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Atridia | Lead sponsor of trials | 2017 to now |
| Jiangsu HengRui Medicine | Lead sponsor of trials | 2018 to now |
| Hengrui Pharmaceutical | Lead sponsor of trials | 2023 to now |
| Shengdi Pharmaceutical | Lead sponsor of trials | 2024 to now |
| Hansoh BioMedical | Lead sponsor of trials | 2024 to now |
| Jiangsu Hansoh Pharmaceutical | Lead sponsor of trials | 2024 to now |